Abstract
We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody responses in stool from a cohort of 44 hospitalized COVID-19 patients. SARS-CoV-2 RNA was detected in stool of 41% of patients and more frequently in patients with diarrhea. Patients who survived had lower fecal viral RNA than those who died. Strains isolated from stool and nasopharynx of an individual were the same. Compared to uninfected controls, COVID-19 patients had higher fecal levels of IL-8 and lower levels of fecal IL-10. Stool IL-23 was higher in patients with more severe COVID-19 disease, and we found evidence of intestinal virus-specific IgA responses associated with more severe disease. We provide evidence for an ongoing humeral immune response to SARS-CoV-2 in the gastrointestinal tract, but little evidence of overt inflammation.
Competing Interest Statement
M.C.D is a consultant for Abbvie, Arena, BMS, Boehringer Ingelheim, Genentech, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target RWE and UCB, has received research support from Janssen, Pfizer, Prometheus Biosciences and Abbvie and is co-founder of Cornerstones Health, Mitest Health, Trellus Health, M.M. is a consultant for Takeda, Genentech, Regeneron, Compugen, Myeloid Therapeutics. F.K. declares that The Icahn School of Medicine at Mount Sinai has filed patent applications regarding SARS-CoV-2 serology assays and has licensed reagents to several commercial entities. J.J.F. serves on the scientific advisor board of Vedanta Biosciences. The remaining authors declare no conflicts of interest.
Funding Statement
This work was supported by grants from the NIH (NIGMS GM108505, NIDDK DK112978, and NIDDK DK124133 to J.J.F and NIDDK DK123749 to S.M. and J.J.F.). G.J.B. is supported by a Research Fellowship Award from the Crohn's and Colitis Foundation of America. M.P.S. is supported by NIH T32 5T32AI007605. H.v.B. and A.S.G.-R were supported in part by the Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400008C and A.S.G-R. was further supported in part by a Robin Chemers Neustein Postdoctoral Fellowship Award. Work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, and the generous support of the JPB foundation, the Open Philanthropy Project (2020-215611) and other philanthropic donations. Computational resources used in this research were further supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under awards S10OD018522 and S10OD026880. The funders had no role in the study design or manuscript preparation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the institutional review board at Icahn School of Medicine at Mount Sinai (Protocol #: HS# 16-00512/ GCO# 16-0583 and HS# 11-01669).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have updated the manuscript to include analysis of SARS-CoV-2 genomes isolated from fecal samples.
Data Availability
16S amplicon and metagenomic sequencing data has been deposited to NCBI under Bioproject PRJNA660883. Viral genomes have been deposited to GISAID and Genbank. De-identified raw source data used to generate all figures is provided in the supplemental information.
